BPC-157 is a synthetic peptide made of 15 amino acids. It is not FDA-approved for any use, and no approved medicine in the United States contains it. BPC stands for body protection compound.
Its sequence is based on part of a larger protein found in human gastric juice, although BPC-157 itself is made in a laboratory. Most published research on it comes from a small number of research groups, much of it from one university in Croatia.
Researchers have proposed a range of mechanisms for BPC-157 based on cell and animal experiments, mostly in models of tissue injury. None of these proposed mechanisms has been confirmed in people.
Nearly all BPC-157 studies have been done in cells and animals. A 2025 systematic review in the HSS Journal found 36 eligible studies of BPC-157 in musculoskeletal medicine, of which 35 were preclinical and one was clinical. A 2025 review in Current Reviews in Musculoskeletal Medicine identified only three small human pilot studies and concluded that rigorous, large-scale trials are lacking.
Results in animals often do not carry over to humans, which is one reason the FDA requires controlled clinical trials before approving any drug. Large, controlled clinical trials of BPC-157 have not been published.
Current status: Not FDA-approved.
BPC-157 was previously on the FDA's Category 2 list of bulk substances that raise significant safety concerns for compounding. The FDA cited a possible risk of immunogenicity (an unwanted immune response), peptide impurities, and no or only limited safety information for the proposed routes of use. On April 15, 2026, the FDA removed BPC-157 and 11 other peptides from Category 2 after their nominations were withdrawn. That removal did not make BPC-157 eligible for compounding.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend adding BPC-157 to the 503A Bulks List, the list of bulk substances pharmacies may use for compounding, for ulcerative colitis, the use the FDA reviewed. FDA staff had recommended against it.
The vote is advisory only. The FDA must make its own decision and complete formal rulemaking, and as of late September 2026 it had not added BPC-157 to the list. Being placed on that list would allow compounding with a prescription; it would not make BPC-157 an FDA-approved drug.
Products sold online as research chemicals or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or sterility.
BPC-157 is also sold in blends with other peptides under marketing names. Those blends are not approved either, and we found no published clinical trials of them as combinations.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names BPC-157 under class S0 (non-approved substances). It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.
Anyone with questions about BPC-157 should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.
See the full list of compound profiles in the Peptide Guide. BPC-157 is often discussed alongside TB-500, and it appears in the BPC-157 and TB-500 blend and the KLOW blend. For the legal background, read whether peptides are legal in the U.S.